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ABSTRACT
Background:Adequate knowledge about the safety of consumption of small-quantity lipid-based nutrient supplements
(SQ-LNSs) is needed.
Objective: We aimed to test the hypothesis that SQ-LNS consumption is noninferior to control with respect to child
morbidity.
Methods: Women (n = 1320) ≤20 wk pregnant were assigned to iron and folic acid until delivery with no
supplementation for offspring; or multiple micronutrient supplements until 6 mo postpartum with no supplementation
for offspring; or SQ-LNSs until 6 mo postpartum, and SQ-LNSs for offspring (6 mg Fe/d) from 6 to 18 mo of age [the
lipid-based nutrient supplement (LNS) group]. We assessed noninferiority (margin ≤20%) between any 2 groups during
0–6mo of age, and between the non-LNS and LNS groups during 6–18mo of age for caregiver-reported acute respiratory
infection, diarrhea, gastroenteritis, fever/suspected malaria, poor appetite, and “other illnesses.”
Results: During 0–6 mo of age, 1197 infants contributed 190,503 infant-days. For all morbidity combined, overall mean
incidence (per 100 infant-days) was 3.3 episodes, overall mean prevalence (percentage of infant-days) was 19.3%, and the
95% CIs of the incidence rate ratio (IRR) and longitudinal prevalence rate ratio (LPRR) between any 2 groups were≤1.20.
During 6–18 mo, there were 240,097 infant-days for the non-LNS group and 118,698 for the LNS group. For all morbidity
combined, groupmean incidences were 4.3 and 4.3, respectively (IRR: 1.0; 95%CI: 1.0, 1.1), andmean prevalences were
28.2% and 29.3%, respectively (LPRR: 1.0; 95%CI: 1.0, 1.1). Noninferiority was inconclusive for diarrhea, fever/suspected
malaria, and poor appetite.
Conclusions: SQ-LNS consumption does not increase reported overall child morbidity in this population compared
with the 2 other treatments. This trial was registered at clinicaltrials.gov as NCT00970866. J Nutr 2019;00:1–12.
Keywords: maternal–infant supplementation, multiple micronutrient supplements, lipid-based nutrient
supplements, infant morbidity, child morbidity
Introduction
In low-income settings, the diets of many people are based
predominantly on cereals and tubers and are of low nutrient
quality (1). The consumption of low-quality diets is associated
with the delivery of low-birth-weight and small-for-gestational-
age (SGA) infants among pregnant women (2–4) and with poor
growth and development among children (5). Currently, efforts
to increase the nutrient intakes of women and children in low-
income settings are an international priority (6, 7).
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The International Lipid-based Nutrient Supplements (iLiNS)
Project developed small-quantity lipid-based nutrient sup-
plements (SQ-LNSs) for enriching home-prepared foods for
women and infants in low-income settings (8), as a potential
strategy to increase nutrient intakes during the “first 1000
days.”A Cochrane review suggests that in women, prenatal SQ-
LNS supplementation, compared with iron and folic acid (IFA),
has positive effects on birth outcomes, including greater infant
weight and length at birth, and lower prevalence of SGA and
newborn stunting (9). Another Cochrane review shows that in
children 6–23 mo of age, the consumption of SQ-LNSs added to
complementary foods improves growth and anemia status when
compared with no intervention, and may be more effective than
other alternatives such as fortified blended foods and multiple
micronutrient powders at improving growth (10).
Despite the positive meta-analysis evidence so far reported
(10), a possible concern about SQ-LNS supplementation for
children is that it might be associated with increased risk of
morbidity, including malaria, as a result of the supplemental
iron provided (11). Adequate knowledge about the safety of
SQ-LNS supplementation among infants and young children
is needed to inform future efforts to scale up the use of such
products. So far, the morbidity results from previous child
lipid-based nutrient supplement (LNS) supplementation trials
have been mixed. In several studies, no differences between
LNS and control groups were reported for diarrhea (12–14),
runny nose (12), fever (12), respiratory infections (12, 14,
15), and malaria (13, 15). Elsewhere, LNS supplementation
reduced diarrhea (16, 17), fever (16, 18), and runny nose (18),
whereas in other settings, it increased diarrhea (18) and possibly
malaria-related nonscheduled visits to a health center (19).
Furthermore, we are aware of only 1 report on child morbidity
thus far (20) from a trial that included a group exposed to LNS
both prenatally (maternal supplementation) and postnatally
(maternal and infant supplementation).
The iLiNS-DYAD trial in Ghana included both pre- and
postnatal SQ-LNS consumption. In Ghana, child undernutrition
has decreased in recent years (21), but micronutrient deficiencies
(22) and childhood morbidity such as diarrhea and respiratory
infections (23) remain common. We reported previously that
SQ-LNS consumption increased fetal growth (24) as well as
child growth (25) and iron status (26) by 18 mo of age. Herein,
we performed a secondary outcome, noninferiority analysis to
determine whether SQ-LNS supplementation was noninferior
to the 2 other supplementation regimens with respect to child
morbidity. We hypothesized that the incidence or longitudinal
prevalence of childhood morbidity among infants provided
with SQ-LNSs from 6 to 18 mo of age, and whose mothers
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were provided with SQ-LNSs during pregnancy and the first
6 mo postpartum, would not be higher than those among
infants who received no supplements from 6 to 18 mo of age,
and whose mothers received IFA during pregnancy only, or
multiple micronutrient supplements (MMNs) during pregnancy
and lactation.
Methods
Trial setting, design, and ethical approval
We have described the iLiNS-DYAD Ghana trial (NCT00970866) in
previous articles (24, 25). With the aim of evaluating the efficacy of
SQ-LNSs for pregnant and lactating women and their infants, the trial
was conducted in the semiurban setting stretching from Somanya to
Kpong in the Eastern Region ∼70 km north of Accra, and was designed
as a partially double-blind, individually randomized, controlled trial
with 3 equal-size groups. Women attending antenatal clinics in 4 main
health centers in the area were eligible if they were ≥18 y old and
≤20 wk pregnant at the time of enrollment. Exclusion criteria were
being a nonresident of the area; intention to relocate from the area
before the expected end of the trial; milk or peanut allergy; participation
in another trial; HIV infection; asthma; epilepsy; tuberculosis; any
malignancy; or unwillingness to participate in trial procedures. Women
signed or thumb-printed informed consents for their own participation,
and for their infants if born alive.
At enrollment, women were randomly assigned to the 3 groups as
follows: 1) the IFA group, assigned to consume 60 mg Fe/d + 400 μg
folic acid/d supplements during pregnancy and 200 mg Ca/d as
placebo during the first 6 mo postpartum, and no supplementation
for offspring; 2) the MMN group, assigned to consume MMNs until
6 mo postpartum, and no supplementation for offspring; and 3) the
LNS group, assigned to consume SQ-LNSs until 6 mo postpartum, and
supplementation for the offspring with SQ-LNSs designed for infants
from 6 to 18 mo of age. All supplements were intended for daily
consumption.
The trial was approved by 3 ethics committees (University of
California, Davis; Ghana Health Service; and Noguchi Memorial
Institute for Medical Research) and monitored by a Data and Safety
Monitoring Board.
Trial supplements
As reported previously (24, 25), the IFA reflected the Ghana Health
Service’s standard micronutrient supplementation for pregnant women
at the time of the study (27). The MMN consisted of 18 vitamins and
minerals at 1 or 2 times the RDA for pregnancy, except for iron, for
which we used 20 mg/d instead of the 30 mg/d in the UNIMMAP
formulation (28) or the 30–60 mg/d in theWHO guideline (27), because
of previous evidence (29) showing that 20 mg Fe/d was as effective as
40 mg Fe/d or 80 mg Fe/d in treating anemia during pregnancy but less
likely to cause gastrointestinal side effects than a 30–60 mg/d dose. The
SQ-LNS designed for pregnant and lactating women (SQ-LNS-P&L)
had the same micronutrient contents as the MMN, and in addition,
energy, protein, essential fatty acids, and the maximum amounts of
calcium,magnesium, phosphorus, and potassium that could be included
given technical and organoleptic constraints (8). With the 20 mg Fe/d
in the SQ-LNS-P&L, it was possible to have just 1 product for both
pregnancy and lactation, assuming that this dose, in addition to iron
from the usual diet, would give a total daily intake that was close to the
amount in the UNIMMAP formulation (28) and would therefore meet
the RDA of 27 mg Fe for pregnancy, while at the same time, it would
not greatly exceed the RDA (9 mg/d) for lactation (8, 30).
The daily dose of the SQ-LNS designed for infants (SQ-LNS-INF)
contained the WHO, WHO/FAO, and FAO Recommended Nutrient
Intakes (RNIs) for key micronutrients for infants 7–12 mo of age,
with a few exceptions (8): the 6.0 mg Fe/d was slightly lower than the
WHO/FAO RNI (6.2 mg/d) and 33% lower than the dose previously
used in Ghana (12), because of concerns about increasing the risk of
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malaria and infections in an area of high malaria endemicity (31);
and the 8 mg Zn/d content (8) was higher than the WHO/FAO RNI
(2.5 mg/d) because of our previous study (12) showing that zinc
absorption may be decreased in the predominantly maize-based diet
high in phytate typically consumed by infants during the complementary
feeding period.
The IFA andMMN supplements as well as the calcium placebo were
provided as capsules in blister packs of 10, whereas the SQ-LNS-P&L
was provided in 20-g sachets, and the SQ-LNS-INF was provided in
10-g sachets. All supplements were meant for daily consumption.
Initial screening, baseline assessments, group
assignments, and blinding
We determined women’s eligibility by using a screening questionnaire,
and with the aid of information recorded from their antenatal cards.
For eligible women agreeing to participate, we collected baseline
information, including sociodemographic characteristics; gestational
age (by using ultrasound biometry, Aloka SSD 500); anthropometric
status (by using standard procedures); blood hemoglobin (Hb)
concentration (HemoCue AG); zinc protoporphyrin concentration
(Hematofluorometer, Aviv Biomedical Co.), and peripheral malaria
parasitemia (Vision Biotech) (24).
Women were randomly assigned after the baseline assessments, as
follows (24, 25): 1) the study statistician at University of California,
Davis, Janet M Peerson, developed the group assignments in blocks of
9 (SAS for Windows version 9.4); 2) the study data manager at the
University of Ghana, who was not involved in enrollment, prepared
opaque envelopes containing the assignments, which were numbered
and stacked by block number; and 3) the study nurse at the field site
performed the random assignment. At each enrollment, the study nurse
shuffled 9 envelopes taken from the top of the stack and asked the
participant to make a pick to reveal the group assignment. The nurse
then returned the unused envelopes to the top of the stack. When there
were <9 women left to be enrolled, the nurse shuffled whatever number
of envelopes remained. Any allocation information was kept securely
by the field supervisor in Ghana and the study statistician at University
of California, Davis, only.
At enrollment, the study nurse gave women a 2-wk supply of
supplements, advice to take 1 capsule/d with water after a meal or one
20-g SQ-LNS-P&L sachet/d mixed with food, and a standard nutrition
message: “Do not forget to eat meat, fish, eggs, fruits, and vegetables
whenever you can; you still need these foods even as you take the
supplements we have given you” (24, 25). We color-coded all blister
packs, so that the study team and participants knew the IFA and MMN
capsules only by their color codes (3 colors for the IFA group and 3 for
the MMN group). We could not blind study workers and participants
with regard to which women received SQ-LNSs and which received the
capsules, but laboratory staff who collected any samples or performed
any laboratory analyses had no knowledge of the group assignments,
and the randomization code was broken only after the analyses of the
primary outcomes had been completed.
Follow-up procedures
Field workers visited pregnant women in their homes biweekly to
provide a fresh supply of supplements and monitor supplement intakes.
All live-born singleton infants were enrolled into the study. In twin
births, 1 infant was randomly selected during the first visit immediately
after birth, and the selected infant was enrolled if he or she was born
alive. After giving birth, women and their infants were visited weekly,
but the women received their supplements or placebo and had intakes
of these monitored biweekly as before.
Women exited the study at 6 mo postpartum, but the weekly visits
for the infants continued. At 6 mo of age, the study nurse gave the
“minimum message” on complementary feeding to all mothers at the
laboratory after the infants had participated in their first laboratory
assessment: “Breastfeed your baby as you did before 6 mo of age; do not
forget to feed your baby meat, fish, eggs, fruits, and vegetables whenever
you can.” During the next usual weekly home visit, field workers
delivered the first supply of SQ-LNS-INFs for infants in the LNS group,
advised the mothers or caregivers on how to feed the supplements (i.e.,
mix the entire content of 1 sachet with 2–3 tablespoons of food for
the infant before feeding additional foods if the infants desire, 2 times
each day), and repeated the “minimum message” on complementary
feeding given by the study nurse. For infants in the other 2 groups not
assigned to any supplements, field workers only repeated the “minimum
message” to the mothers or caregivers. Field workers delivered a fresh
supply of infants’ SQ-LNSs during the usual weekly visits, but the
“minimum message” was not repeated again thereafter. Infants exited
the study at 18 mo of age.
Measurement of outcome variables
At each weekly home visit for study infants, field workers collected
caregivers’ reports of common morbidity symptoms experienced by the
infants, as well as the infants’ nonscheduled visits to any “treatment
points” with the purpose to receive treatment of illness, during the
period since the last visit or the last 10 d, if the current visit was delayed
for >10 d. We defined “treatment points” to include hospitals, clinics,
health posts, private physicians, pharmacists, nurses, midwives, drug
stores not operated by pharmacists, and traditional healers, because
residents of the study area typically seek treatment of illnesses from
all such quarters, and therefore focusing on hospitals and clinics alone
would underestimate treatments of morbidity. Whenever an infant
was reportedly taken for a nonscheduled visit to a treatment point
because of illness, the field worker asked about the specific illnesses that
precipitated the nonscheduled visit.
To facilitate data collection, field workers trained caregivers to
use a calendar grid with pictures in its rows depicting the common
morbidity symptoms (diarrhea, vomiting due to illness, fever, cough,
nasal discharge, and poor appetite) and a visit to a treatment point,
to record information. The calendar grid had columns for recording
information for each day ≤10 d. At each visit, field workers transferred
the information recorded by the caregiver on the calendar grid onto a
morbidity form after verification with the caregiver, and in addition,
asked if the child had rapid breathing or difficult breathing on any
day during the period. As much as possible, all morbidity data were
collected using the daily calendar grid. As a complementary strategy,
we asked fathers, older children, and other key members within the
households to remind mothers about entering the children’s morbidity
information on the calendar each day. With the intense weekly home
visits by field workers, the filling out of the morbidity calendar soon
became the normal daily routine for mothers and families. If a mother
missed filling out the calendar grid, it was generally for a few days within
the week and not the entire week or any longer period of time. If, during
the weekly home visit, a field worker found that a mother had missed
filling out the calendar on some days, the field worker probed themother
to determine if the child had any morbidity symptoms or was taken to
any treatment centers on those days.
Several trials across Africa have used a calendar grid to collect
children’s morbidity data, including some in Malawi (15, 19) and South
Africa (18), as well as our own earlier trial in Ghana (12). Work by
Arnold et al. (32) testing the use of the daily calendar in 5 countries
to determine the optimal recall period for caregiver-reported illness
in children <24 mo of age recommended the use of a 7-d (weekly)
recall period compared with a 2-d recall period, owing to the increased
statistical efficiency (e.g., reduced sample sizes required) that resulted
from the use of the former.
The morbidity outcome variables were evaluated for 2 time
periods, namely 1) 0–6 mo of age [the period when the WHO
recommends exclusive breastfeeding (33), during which no infants
directly consumed any study supplements] and 2) 6–18 mo of age
(the period of complementary feeding during which infants in the
LNS group consumed SQ-LNSs, and those in the IFA and MMN
groups did not consume any study supplements). The outcome variables
were 1) the incidence and longitudinal prevalence of caregiver-reported
common morbidity episodes, and 2) the incidence of caregiver-reported
nonscheduled visits to a “treatment point” because of illness. The
morbidity episodes were 1) acute respiratory infection (ARI),2) diarrhea
(caregiver-defined), 3) gastroenteritis, 4) fever or suspected malaria,
5) “other illnesses,” and 6) poor appetite. We separated caregivers’
SQ-LNS supplementation and infant morbidity 3
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diagnosis of diarrhea from gastroenteritis or the clinical definition of
diarrhea (34) because of evidence that there may be a discrepancy
between caregivers’ diagnosis of diarrhea and the one defined by
the clinical criteria (35). The diagnoses of gastroenteritis, ARI, and
suspected malaria were derived from a combination of symptoms
occurring for ≥1 d, while ensuring that diagnoses were mutually
exclusive. We defined acute gastroenteritis as vomiting or diarrhea
for ≥3d, or both for ≥1 d (36); diarrhea as passage of ≥3 loose stools
in the past 24 h (34) regardless of other symptoms; ARI as cough,
rapid breathing, difficult breathing, or nasal discharge in the absence
of diarrhea regardless of fever; fever or suspected malaria as increased
body temperature in the absence of diarrhea and ARI, with or without
other symptoms; and “other illnesses”as other symptoms in the absence
of diarrhea, ARI, or fever. For all illnesses, we defined an episode as the
period starting from the day the child had symptoms when preceded
by ≥2 d of no symptoms or data. An episode lasted until the last day
the child had symptoms which was then followed by ≥2 symptom-free
days (19). The number of days that a child was at risk of each of the
symptoms (i.e., not already exhibiting that symptom) was calculated,
accounting for the mutually exclusive definitions.
We calculated the incidence of a morbidity episode as the number of
episodes divided by the total days at risk, and longitudinal prevalence
as the percentage of follow-up days that the infant had the illness (37).
The incidence of nonscheduled visits to a treatment point was defined as
the total number of nonscheduled visits divided by the total number of
follow-up days.We calculated the incidence of treatment point visits due
to all morbidity events combined, as well as the incidence of treatment
point visits due to the specific morbidity events that precipitated the
visits. We used “other reasons” for treatment point visits to represent
visits made that were not due to any of the morbidity events listed.
Sample size and data analysis
The sample size for the iLiNS-DYAD-Ghana trial (24, 25) was based on
detecting an effect size or Cohen’s d (38) of ≥0.3 between any 2 groups
for the primary continuous outcomes (child length at birth and child
length by 18 mo of age), with a 2-sided 5% test and 80% power, given
3 intervention groups. A total of 1320 women were enrolled after a
temporary mislabeling of some IFA and MMN supplements, which we
reported previously (24, 25). In our trial protocol at clinicaltrials.org, as
well as the general statistical analysis plan (SAP) for the iLiNS-DYAD-
Ghana trial, which we posted at our website (www.ilins.org) before
any analyses began, we listed child morbidity as one of the secondary
outcomes to be analyzed separately. An additional, more detailed SAP
was developed specifically for this present analysis and finalized before
data analysis began.We performed all analyses by using SAS version 9.4
(SAS Institute) and the complete case intention-to-treat principle (39).
That is, data for all infants were included in the analysis, regardless of
the number of days supplements were consumed by the infants or their
mothers. Children who dropped out of the study were included in the
analysis up until the date of dropout or last known date of morbidity
information.
As reported previously, the self-reported adherence to supplement
intake for women (pregnancy/lactation) was 88.1%/85.7% for the IFA
group, 87.0%/85.0% for the MMN group, and 83.7%/80.0% for the
LNS group (40), and that for the infants in the LNS group was 73.5%
(25).
We summarized background maternal and household variables by
intervention groups according to the supplements women were assigned
to at enrollment, as done previously (24, 25). For each outcome variable,
we calculated the mean incidence or longitudinal prevalence by group,
and compared group mean incidence or longitudinal prevalence by
using noninferiority testing (15, 19). For comparing mean incidence,
we calculated the incidence rate ratio (IRR—ratio of the incidence rate
in the treatment group to the incidence rate in the comparison group),
along with its 95% CI. Incidence and IRR (95% CI) were generated
using negative binomial regression models (SAS PROC GLIMMIX).
The negative binomial models used an offset to adjust for the number
of follow-up days for each child. For comparing mean longitudinal
prevalence, we calculated longitudinal prevalence rate ratio (LPRR)
as the ratio of the longitudinal prevalence in the intervention group
to the longitudinal prevalence in the control group, and its 95% CI.
Longitudinal prevalence and LPRR (95% CI) were generated using log-
linear least-squares regression (SAS PROC GLIMMIX).
For the noninferiority testing, we predefined a noninferiority
margin (δ) of no more than a 20% increase in an outcome for the
intervention group compared with the control group. There is no
standard noninferiority margin for assessing safety in micronutrient
supplementation trials for children, but a similar margin has been used
in several such contexts, including 2 trials in Bangladesh (14, 41) and
2 in Malawi (15, 19). This would mean that if a child in the non-
LNS group were expected to have 5 morbidity episodes during the
period from birth to 6 mo of age, or from 6 to 18 mo of age, we
would tolerate only a mean of 1 additional episode during the period
for children in the LNS group. The 20% margin is consistent with
the 10–20% range of margins often thought of as acceptable (42),
and in this case choosing the upper end of this range is consistent
with various guidance documents (43, 44) and other studies (41) that
support the selection of a wider noninferiority margin if a product offers
an advantage in some other aspect of its profile. Based on available
evidence (10), we considered that the LNSs met this condition. For any
outcome, our noninferiority hypothesis was based on the comparison
of the upper bound of the 2-sided 95% CI for the IRR or LPRR
to the prespecified noninferiority margin of ≤1.2, in accordance with
CONSORT 2010 guidelines (45).We anticipated the following possible
conclusions: superiority of the intervention group compared with the
control group if the upper bound of the 2-sided 95% CI for the IRR or
LPRR was <1.0; noninferiority if the upper bound of the 95% CI of the
IRR or LPRR was ≤1.2; inconclusive noninferiority if the lower bound
of the 95% CI of the IRR or LPRR was <1.2 and the upper bound
was >1.2; or inferiority, if the lower bound of the 95% CI for the IRR
or LPRR was >1.2 (45, 46).
In the analysis of outcomes during 0–6 mo of age, we compared
infants in all 3 groups according to the supplements women were
assigned to at enrollment, and for the analysis of outcomes during 6–
18 mo of age, we compared infants in the LNS group (who consumed
the SQ-LNSs) with those in the IFA and MMN groups combined (who
did not consume any supplements). In the text, we have presented
statistics on background characteristics as means ± SDs (continuous
outcomes) or percentages (binary outcomes), and on the outcome
variables as ratios and their 95% CIs.
Results
The iLiNS-DYAD-Ghana trial data were collected between
December, 2009 and March, 2014. At enrollment, the women’s
mean age was ∼27 y, they had nearly 8 y of formal education,
and were ∼16 wk pregnant (Table 1). Further, about one-
third of the women were nulliparous, 10% tested positive in
the rapid diagnostic test for malaria, and 14% were anemic
when using the Hb concentration cutoff of <100 g/L (47).
These background characteristics were comparable across the
3 groups.
A total of 1257 infants were born to the women in the study,
of whom 1228 were enrolled; the remaining 29 not enrolled
were stillborn (Figure 1). Nearly (n = 1185) all of the infants
enrolled completed the study at 18 mo of age, except 27 who
died, 9 whose parents refused, and 7 who relocated. Apart from
having a greater mean± SD housing index (0.3± 1.0 compared
with −0.01 ± 1.00; P = 0.034), the dropouts did not differ
in background characteristics from those who completed the
study.
During the period 0–6 mo of age, there were 1197 infants
in the study, who contributed >190,000 infant-days of follow-
up for the 3 groups. During this period, the overall mean
incidence and mean longitudinal prevalence of all morbidity
events combined were 3.3 episodes per 100 infant-days and
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TABLE 1 Characteristics of women (n = 1320) who participated in the iLiNS-DYAD-Ghana
micronutrient supplementation trial, by group according to supplements women were assigned to
when enrolled1
Characteristics at enrollment IFA (n = 441) MMN (n = 439) LNS (n = 440)
Age, y 26.5 ± 5.2 (441) 26.7 ± 5.7 (439) 26.9 ± 5.6 (440)
Formal education, y 7.8 ± 3.6 (441) 7.6 ± 3.5 (439) 7.6 ± 3.9 (440)
Weeks of gestation 16.2 ± 3.3 (438) 16.0 ± 3.2 (438) 16.1 ± 3.3 (435)
Asset index2 0.05 ± 1.01 (433) 0.05 ± 0.99 (431) − 0.09 ± 1.00 (432)
Housing index2 0.05 ± 0.98 (433) − 0.03 ± 1.02 (431) − 0.01 ± 1.00 (432)
HFIAS score3 2.8 ± 4.6 (436) 2.4 ± 4.1 (429) 2.6 ± 4.0 (432)
Married or cohabiting 406/441 (92.1) 413/439 (94.1) 405/440 (92.0)
Primiparous women 162/441 (36.7) 137/439 (31.2) 147/440 (33.4)
Positive malarial RDT4 40/441 (9.1) 39/438 (8.9) 54/440 (12.3)
Anemic5 55/441 (12.5) 70/438 (16.0) 60/440 (13.6)
1Values are mean ± SD (n) or n/total n (%). IFA group randomly assigned to receive 60 mg Fe and 400 μg folic acid/d during
pregnancy and 200 mg Ca/d as placebo during the first 6 mo postpartum; LNS group randomly assigned to receive 20 g/d small-
quantity LNS until 6 mo postpartum; MMN group randomly assigned to receive 18 vitamins and minerals (including 20 mg Fe)/d until
6 mo postpartum. The small-quantity LNS had the same micronutrients as the MMN group, plus 4 more minerals (Ca, P, K, and Mg)
and macronutrients. HFIAS, Household Food Insecurity Access Scale; IFA, iron and folic acid; LNS, lipid-based nutrient supplement;
MMN, multiple micronutrient supplement; n, number of participants whose response was “yes” for the variable in question; RDT,
rapid diagnostic test; total n, the number of participants in the group in question.
2Proxy indicators for household socioeconomic status; higher values represent higher socioeconomic status.
3HFIAS is a proxy indicator for household food insecurity (1); higher values represent higher food insecurity.
4Clearview Malarial Combo, Vision Biotech.
5Anemia defined as blood hemoglobin concentration <100 g/L (2).
19.3% of infant-days, respectively. In each of the pairwise
comparisons, the 95% CIs of the IRR (Table 2) or LPRR
(Table 3) for all reported morbidity events combined were≤1.2,
suggesting noninferiority between any 2 groups. Concerning
specific reported morbidity outcomes, there was a similar
pattern of noninferiority between groups in the IRR (Table 2)
or LPRR (Table 3) for ARI. However, the upper bounds of the
95% CIs of the IRRs or LPRRs for diarrhea (caregiver-defined),
gastroenteritis, fever/suspected malaria, “other illness,” and
poor appetite generally exceeded the noninferiority margin
of 1.20, which suggested inconclusive noninferiority between
the groups in pairwise comparisons. During 0–6 mo of age,
the overall mean incidence of all reported nonscheduled
treatment point visits combined was 1.0 per 100 infant-days
(Table 4). Most of these unscheduled visits were due to
gastroenteritis, ARI, and fever/suspected malaria. In general,
there was noninferiority between groups in the IRR of all
nonscheduled visits combined, or nonscheduled visits due to
ARI. However, there was generally inconclusive noninferiority
between groups in the IRRs of nonscheduled visits due to
gastroenteritis, fever/suspected malaria, “other illness,” and
poor appetite.
From 6 to 18 mo of age, the infants in the IFA and MMN
groups combined contributed 240,097 infant-days of follow-up,
whereas those in the LNS group contributed 118,698 infant-
days of follow-up. During this period, the mean incidence and
longitudinal prevalence of most of the morbidity events in
the LNS group were noninferior to the corresponding mean
incidence and longitudinal prevalence in the IFA + MMN
groups (non-LNS group) combined (Table 5). Results for
the incidence of “other illness” and poor appetite, and the
longitudinal prevalence of these 2 symptom categories as well
as fever/suspected malaria and diarrhea (caregiver report) were
inconclusive, with the upper bounds of the 95% CIs of the
IRRs exceeding the 1.2 noninferiority threshold by 0.06–0.09,
and the upper bounds of the 95% CIs of the LPRRs exceeding
the noninferiority threshold by 0.06–0.18. As shown in
Table 6, the LNS group was noninferior to the non-LNS group
with regard to the overall nonscheduled visits to a treatment
point, or such visits resulting from ARI, gastroenteritis, or
poor appetite. Noninferiority of the LNS group compared
with the non-LNS group could not be established with respect
to the incidence of visits to a treatment point because of
fever/suspected malaria and “other reasons.”
Discussion
In this semiurban setting in Ghana, infant morbidity during
the first 6 mo of life was not increased by the provision of
any of the maternal supplements (IFA, MMN, or SQ-LNS),
compared with infants whose mothers received either of the
other 2 supplements. Similarly, child incidence and longitudinal
prevalence of all morbidity events (combined) between 6 and
18 mo of age were not increased by the provision of SQ-
LNSs to mothers and then to their offspring from 6 to 18 mo,
compared with children who did not receive SQ-LNSs and
whose mothers received IFA or MMNs, nor was the incidence
of ARI, diarrhea, gastroenteritis, or fever/suspected malaria.We
could not conclude noninferiority with regard to the prevalence
of diarrhea and fever/suspected malaria, nor the incidence or
prevalence of poor appetite, when comparing children provided
with SQ-LNSs with those not provided with any supplements,
but those results were close to the noninferiority margin
threshold of 1.2.
Our results that SQ-LNS consumption did not increase
overall child morbidity agree with those from the iLiNS-DOSE
trial in Malawi (19), in which the incidence of all caregiver-
reported diseases combined was not greater in children assigned
to 10, 20, or 40 g LNS/d during 6–18 mo of age, than in
the control group which received no supplementation. Similar
results were found in the iLiNS-DOSE trial (19) for longitudinal
prevalence of all childhood morbidity symptoms combined
(19), except for the group receiving 20 g LNS/d, in which
noninferiority could not be concluded compared with control.
In the iLiNS-DOSE trial, the provision of LNSs to infants
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FIGURE 1 Study profile showing infants whose mothers were enrolled into the trial, and the reasons some infants were lost to follow-up. IFA
group: infants were assigned to receive no supplements, whereas their mothers were assigned to receive 60 mg Fe and 400 μg folic acid/d
during pregnancy and 200 mg Ca/d as placebo during 6 mo postpartum; MMN group: infants were assigned to receive no supplements, whereas
their mothers were assigned to receive 1 multiple micronutrient capsule/d containing 18 vitamins and minerals (including 20 mg Fe/d during
pregnancy and the first 6 mo postpartum); LNS group: infants were assigned to receive 20 g LNS/d (designed for infants) containing 6 mg Fe/d
from 6 to 18 mo of age, whereas their mothers received 20 g LNS/d (designed for women) with the same micronutrients as the MMN group
during pregnancy and the first 6 mo postpartum. Both LNS products contained 4 additional minerals (Ca, P, K, and Mg) as well as macronutrients.
IFA, iron and folic acid; LNS, lipid-based nutrient supplement; MMN, multiple micronutrient supplement.
did not decrease breastmilk intakes at 9–10 mo of age (48),
and in Ghana, Burkina Faso, and Malawi, LNS consumption
had no adverse effects on reported infant and young child
feeding practices (continued breastfeeding or the frequency of
breastfeeding) at 18 mo of age (49). The lack of adverse effects
of SQ-LNS consumption on overall morbidity in our sample
is consistent with the finding that SQ-LNSs do not reduce the
intakes of breastmilk and its bioactive components that offer
protection against infectious diseases (50, 51).
With regard to caregiver-reported ARI, diarrhea, gastroen-
teritis, and fever/suspectedmalaria, our results are also generally
comparable with those of other LNS supplementation trials.
For ARI, our findings of noninferiority of the LNS group in
incidence and prevalence during 0–6 mo of age and 6–18 mo of
age agree with those from Ghana (12), Malawi (15, 19), Haiti
(52), Bangladesh (14, 20), Zimbabwe (53), and South Africa
(18), which showed no group differences or demonstrated
noninferiority of the LNS group compared with controls in the
incidence or prevalence of cough (12, 15, 19, 20, 52), nasal
discharge (12, 19, 20), rapid or difficult breathing (20, 53), or a
combination of various acute respiratory symptoms regardless
of fever (12, 14, 15, 19, 52). In the South Africa study (18),
the consumption of 20 g/d regular LNSs or LNSs containing
additional n–3 and n–6 fatty acids, lysine, and phytase from
6 to 12 mo of age reduced the prevalence of cough and difficulty
breathing, compared with no supplementation, but only the
regular LNSs reduced the prevalence of nasal discharge and the
incidence of difficulty breathing. The n–3 fatty content of the
LNSs may be related to their beneficial effects on ARIs in the
South Africa study (54).
For diarrhea, the pairwise comparisons of incidence and
prevalence from birth to 6 mo of age suggest that the
3 groups were indistinguishable from each other with respect
to those outcomes during that period. This is similar to
results from Bangladesh (20), where diarrheal morbidity
from birth to 6 mo of age did not differ between infants
whose mothers received different nutrient supplements during
pregnancy and postpartum, and the infants themselves received
no supplementation. During 6–18 mo of age, our results for
the LNS compared with non-LNS groups add to the mixed
findings across studies regarding the association between LNS
consumption and diarrheal morbidity in children. Whereas
6 Adu-Afarwuah et al.
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TABLE 2 Incidence of caregiver-reported morbidity events during 0–6 mo of age among infants born to pregnant women enrolled in
the iLiNS-DYAD-Ghana micronutrient supplementation trial, by group according to supplements women were assigned to when
enrolled1
Incidence (per 100 infant-days), by group2 IRR of pairwise groups (95% CI)2
IFA (63,119
infant-days)
MMN (65,054
infant-days)
LNS (62,330
infant-days) MMN vs IFA LNS vs IFA LNS vs MMN
All morbidity events combined 3.35 3.21 3.27 0.95 (0.85, 1.07)3 0.98 (0.87, 1.09)3 1.02 (0.91, 1.14)3
Acute respiratory infections 2.53 2.40 2.40 0.95 (0.83, 1.10)3 0.95 (0.83, 1.09)3 1.00 (0.87, 1.15)3
Diarrhea (caregiver-defined) 0.52 0.53 0.55 1.04 (0.81, 1.34) 1.08 (0.84, 1.39) 1.04 (0.81, 1.33)
Gastroenteritis 0.70 0.70 0.70 1.02 (0.80, 1.29) 1.02 (0.80, 1.20)3 1.00 (0.79, 1.28)
Fever/suspected malaria 0.68 0.63 0.69 0.92 (0.71, 1.19)3 1.01 (0.78, 1.29) 1.09 (0.85, 1.41)
Other illness 0.10 0.10 0.11 0.97 (0.61, 1.54) 1.08 (0.69, 1.68) 1.11 (0.71, 1.74)
Poor appetite 0.23 0.23 0.29 1.01 (0.72, 1.42) 1.29 (0.94, 1.78) 1.28 (0.93, 1.76)
1n = 397, 403, and 397 for the IFA, MMN, and LNS groups, respectively. IFA group: infants of women assigned to 60 mg Fe/d and 400 μg folic acid/d during pregnancy and
200 mg Ca/d as placebo during the first 6 mo postpartum, with no supplementation for the offspring; MMN group: infants of women assigned to multiple micronutrient capsules
containing 18 vitamins and minerals (including 20 mg Fe/d) during pregnancy and the first 6 mo postpartum, with no supplementation for the offspring; LNS group: infants of
women assigned to 20 g LNS/d with the same micronutrients as the MMN group during pregnancy and the first 6 mo postpartum, and with the offspring assigned to 20 g
LNS/d (for infants) containing 6 mg Fe/d from 6 to 18 mo of age. The LNS products contained calcium, phosphorous, potassium, and magnesium as well as macronutrients.
All supplements were intended for daily consumption. IFA, iron and folic acid; IRR, incidence rate ratio; LNS, lipid-based nutrient supplement; MMN, multiple micronutrient
supplement.
2Incidence (per 100 infant-days) was calculated by dividing the number of morbidity episodes by the total number of days at risk and multiplying the results by 100. IRR is the
ratio of the incidence in the treatment group to the incidence in the comparison group. Incidence and IRR (95% CI) were generated using negative binomial regression models
(SAS PROC GLIMMIX) and adjusting for the number of follow-up days for each child.
3Noninferiority is concluded.
similar findings of noninferiority of the LNS group in the
incidence of diarrhea were reported in Bangladesh (14) and
Burkina Faso (13), contrasting findings were reported inMalawi
(15), where noninferiority to no supplementation could not
be concluded, and South Africa (18), where 2 types of LNS
products both increased the incidence of diarrhea. With regard
to diarrheal prevalence, the upper limit of the 95% CI of
the LPRR when comparing the LNS with the non-LNS group
in our study (0.9, 1.3) was very close to 1.2 (Table 5), so
our results are in general agreement with those of other
studies showing no group differences (12, 13, 52, 53, 55) or
a decrease (17), but not with others in which LNS consumption
increased the prevalence of diarrhea (18, 20). The results for
gastroenteritis follow the same pattern as those for diarrhea:
first, maternal supplementation did not seem to affect the
incidence or prevalence from birth to 6 mo of age when the
infants did not consume any supplements directly; and second,
the results for 6–18 mo of age (noninferiority of LNSs in the
incidence and prevalence of gastroenteritis) agree with some
previous findings (19) and contrast with others (18).
There are several potential explanations for the differences
in results across studies regarding LNS consumption and
diarrheal morbidity or gastroenteritis in children. These include
variability in the definition of diarrheal episodes across studies
(56), possible over-reporting when group allocations could not
be blinded (18), and contextual factors linked to diarrheal
morbidity, such as poor household water quality (57) and
environmental sanitation (58, 59), cultural norms, and poverty
TABLE 3 Longitudinal prevalence of caregiver-reported morbidity events during 0–6 mo of age among infants born to pregnant
women enrolled in the iLiNS-DYAD-Ghana micronutrient supplementation trial, by group according to supplements women were
assigned to when enrolled1
Longitudinal prevalence, by group2 LPRR of pairwise groups (95% CI)2
IFA (63,119
infant-days)
MMN (65,054
infant-days)
LNS (62,330
infant-days) MMN vs IFA LNS vs IFA LNS vs MMN
All morbidity events combined 19.60 19.08 19.40 0.95 (0.82, 1.11)3 0.98 (0.85, 1.15)3 1.03 (0.89, 1.20)3
Acute respiratory infections 14.74 14.42 14.19 0.98 (0.82, 1.16)3 0.96 (0.81, 1.14)3 0.98 (0.83, 1.17)3
Diarrhea (caregiver-defined) 2.67 2.86 2.90 1.07 (0.74, 1.56) 1.09 (0.75, 1.58) 1.01 (0.70, 1.47)
Gastroenteritis 2.44 2.70 2.91 1.11 (0.79, 1.54) 1.19 (0.86, 1.66) 1.08 (0.78, 1.50)
Fever/suspected malaria 1.35 1.12 1.32 0.84 (0.61, 1.14)3 0.98 (0.72, 1.34) 1.18 (0.86, 1.60)
Other illness 0.42 0.38 0.50 0.89 (0.37, 2.14) 1.17 (0.50, 2.77) 1.31 (0.55, 3.11)
Poor appetite 0.93 0.83 1.22 0.90 (0.56, 1.44) 1.32 (0.82, 2.11) 1.47 (0.92, 2.35)
1n = 397, 403, and 397 for the IFA, MMN, and LNS groups, respectively. IFA group: infants of women assigned to 60 mg Fe/d and 400 μg folic acid/d during pregnancy and
200 mg Ca/d as placebo during the first 6 mo postpartum, with no supplementation for the offspring; MMN group: infants of women assigned to multiple micronutrient capsules
containing 18 vitamins and minerals (including 20 mg Fe/d) during pregnancy and the first 6 mo postpartum, with no supplementation for the offspring; LNS group: infants of
women assigned to 20 g LNS/d with the same micronutrients as the MMN group during pregnancy and the first 6 mo postpartum, and with the offspring assigned to 20 g
LNS/d (for infants) containing 6 mg Fe/d from 6 to 18 mo of age. The LNS products contained calcium, phosphorous, potassium, and magnesium as well as macronutrients.
All supplements were intended for daily consumption. IFA, iron and folic acid; LNS, lipid-based nutrient supplement; LPRR, longitudinal prevalence rate ratio; MMN, multiple
micronutrient supplement.
2Longitudinal prevalence is the percentage of infant-days of follow-up in which infants had morbidity events. LPRR is the ratio of the longitudinal prevalence of caregiver-reported
morbidity symptoms in the treatment group to the longitudinal prevalence of caregiver-reported morbidity symptoms in the comparison group. Longitudinal prevalence and LPRR
(95% CI) were generated using log-linear least-squares regression (SAS PROC GLIMMIX).
3Noninferiority is concluded.
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TABLE 4 Incidence of caregiver-reported nonscheduled visits to a “treatment point” due to morbidity events during 0–6 mo of age
among infants born to pregnant women enrolled in the iLiNS-DYAD-Ghana micronutrient supplementation trial, by group according to
supplements women were assigned to when enrolled1
Incidence (per 100 infant-days), by group2 IRR of pairwise groups (95% CI)2
IFA (63,119
infant-days)
MMN (65,054
infant-days)
LNS (62,330
infant-days) MMN vs IFA LNS vs IFA LNS vs MMN
All nonscheduled visits 1.03 0.99 0.95 0.97 (0.81, 1.16)3 0.92 (0.76, 1.10)3 0.96 (0.79, 1.15)3
Due to acute respiratory infection 0.32 0.31 0.29 0.98 (0.74, 1.25) 0.91 (0.70, 1.19)3 0.95 (0.72, 1.23)
Due to gastroenteritis 0.17 0.20 0.18 1.21 (0.83, 1.76) 1.09 (0.74, 1.60) 0.90 (0.62, 1.30)
Due to fever/suspected malaria 0.21 0.18 0.21 0.83 (0.57, 1.21)3 1.01 (0.70, 1.46) 1.20 (0.83, 1.75)
Due to “other illness” 0.21 0.19 0.15 0.91 (0.59, 1.38) 0.74 (0.48, 1.14)3 0.82 (0.53, 1.27)
Due to poor appetite 0.03 0.01 0.02 0.41 (0.15, 1.10)3 0.59 (0.24, 1.42) 1.44 (0.48, 4.33)
1n = 397, 403, and 397 for the IFA, MMN, and LNS groups, respectively. IFA group: infants of women assigned to 60 mg Fe/d and 400 μg folic acid/d during pregnancy and
200 mg Ca/d as placebo during the first 6 mo postpartum, with no supplementation for the offspring; MMN group: infants of women assigned to multiple micronutrient capsules
containing 18 vitamins and minerals (including 20 mg Fe/d) during pregnancy and the first 6 mo postpartum, with no supplementation for the offspring; LNS group: infants of
women assigned to 20 g LNS/d with the same micronutrients as the MMN group during pregnancy and the first 6 mo postpartum, and with the offspring assigned to 20 g LNS/d
(for infants) containing 6 mg Fe/d from 6 to 18 mo of age. The LNS products contained calcium, phosphorous, potassium, and magnesium as well as macronutrients. Treatment
centers are defined to include hospitals, clinics, health posts, pharmacies, private physicians, nurses, midwives, drug stores not operated by pharmacists, and traditional healers,
typically used by residents of the area. There is no row for diarrhea based on mothers’ definition because visits to treatment points due to caregivers’ diagnosis of diarrhea
overlapped with those due to gastroenteritis. We elected to show visits due to gastroenteritis only, to avoid double-reporting. IFA, iron and folic acid; IRR, incidence rate ratio;
LNS, lipid-based nutrient supplement; MMN, multiple micronutrient supplement.
2Incidence (per 100 infant-days) was calculated by dividing the number of treatment point visits by the total number of follow-up days, and multiplying the results by 100. IRR
is the ratio of the incidence in the treatment group to the incidence in the comparison group. Incidence and IRR (95% CI) were generated using negative binomial regression
models (SAS PROC GLIMMIX) and adjusting for the number of follow-up days for each child.
3Noninferiority is concluded.
(57). Other possible factors affecting the risk of diarrhea or
gastroenteritis among children consuming LNSs, which may
vary by setting, include the effects of unabsorbed iron on the
presence of pathogenic bacteria in the gut (60, 61) or the irritant
effect of iron on gut motility (62, 63).
Regarding fever/suspected malaria, our results are generally
consistent with previous reports from Ghana (12), Haiti (52),
Bangladesh (20), Malawi (15, 19), and South Africa (18). In
those studies, the LNS groups (including the 2 LNS formulations
used in South Africa) did not differ (12, 20, 52), or were
noninferior (15, 19), or had a lower (18) prevalence of
fever/suspected malaria compared with controls, or the LNS
group did not differ (18) or was noninferior (15, 19) in
incidence of fever/suspected malaria compared with controls.
Although there have been concerns about providing iron via
LNSs in malaria-endemic regions such as Ghana, current WHO
recommendations (64) indicate that iron supplementation may
be implemented in malaria-endemic regions provided that the
supplementation is done along with public health measures
to prevent, diagnose, and treat malaria. At the time of our
study, various malaria-control interventions (e.g., distribution
of insecticide-treated bed-nets, vector control) were routinely
TABLE 5 Incidence and longitudinal prevalence of caregiver-reported morbidity events during 6–18 mo of age among infants born to
the pregnant women enrolled in the iLiNS-DYAD-Ghana micronutrient supplementation trial, by group according to supplements
women were assigned to when enrolled1
Incidence (per 100 infant-days)2 Longitudinal prevalence3
IFA + MMN
(240,097 infant-days)
LNS (118,698
infant-days) IRR (95% CI)
IFA + MMN (240,097
infant-days)
LNS (118,698
infant-days) LPRR (95% CI)
All morbidity events combined 4.25 4.32 1.02 (0.96, 1.08)4 28.23 29.29 1.04 (0.96, 1.12)4
Acute respiratory infection 3.43 3.50 1.02 (0.94, 1.11)4 19.90 20.54 1.03 (0.94, 1.13)4
Diarrhea (caregiver-defined) 0.79 0.83 1.05 (0.93, 1.19)4 3.12 3.34 1.07 (0.91, 1.26)
Gastroenteritis 0.88 0.89 1.02 (0.90, 1.15)4 2.64 2.58 0.98 (0.84, 1.14)4
Fever/suspected malaria 0.81 0.87 1.07 (0.95, 1.19)4 1.77 2.00 1.13 (0.98, 1.31)
Other illness 0.20 0.19 0.94 (0.71, 1.26) 0.78 0.64 0.83 (0.55, 1.25)
Poor appetite 1.00 1.18 1.16 (1.05, 1.29) 7.39 8.75 1.18 (1.02, 1.38)
1n = 797 and 391 for the IFA + MMN and LNS groups, respectively. IFA + MMN, IFA group and MMN group combined; IFA group: infants of women assigned to 60 mg
Fe/d and 400 μg folic acid/d during pregnancy and 200 mg Ca/d as placebo during the first 6 mo postpartum, with no supplementation for the offspring; MMN group: infants
of women assigned to multiple micronutrient capsules containing 18 vitamins and minerals (including 20 mg Fe/d) during pregnancy and the first 6 mo postpartum, with no
supplementation for the offspring; LNS group: infants of women assigned to 20 g LNS/d with the same micronutrients as the MMN group during pregnancy and the first 6 mo
postpartum, and with the offspring assigned to 20 g LNS/d (for infants) containing 6 mg Fe/d from 6 to 18 mo of age. The LNS products also contained calcium, phosphorous,
potassium, and magnesium as well as macronutrients. All supplements were intended for daily consumption. IFA, iron and folic acid; IRR, incidence rate ratio; LNS, lipid-based
nutrient supplement; LPRR, longitudinal prevalence rate ratio; MMN, multiple micronutrient supplement.
2Incidence (per 100 infant-days) was calculated by dividing the number of morbidity episodes by the total number of days at risk and multiplying the results by 100. IRR is the
ratio of the incidence in the treatment group to the incidence in the comparison group. Incidence and IRR (95% CI) were generated using negative binomial regression models
(SAS PROC GLIMMIX) and adjusting for the number of follow-up days for each child.
3Longitudinal prevalence is the percentage of infant-days of follow-up in which infants had morbidity events. LPRR is the ratio of the longitudinal prevalence of caregiver-reported
morbidity symptoms in the treatment group to the longitudinal prevalence of caregiver-reported morbidity symptoms in the comparison group. Longitudinal prevalence and LPRR
(95% CI) were generated using log-linear least-squares regression (SAS PROC GLIMMIX).
4Noninferiority is concluded.
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TABLE 6 Incidence of caregiver-reported nonscheduled visits to a “treatment point” due to all
morbidity events combined and to specific morbidity events during 6–18 mo of age among infants
born to the pregnant women enrolled in the iLiNS-DYAD-Ghana micronutrient supplementation trial,
by group according to supplements women were assigned to when enrolled1
Incidence (per 100 infant-days)2
IFA + MMN
(240,097 infant-days)
LNS
(118,698 infant-days) IRR (95% CI)
All nonscheduled visits 1.68 1.71 1.03 (0.94, 1.12)3
Due to acute respiratory infection 0.40 0.39 0.98 (0.84, 1.14)3
Due to gastroenteritis 0.33 0.31 0.93 (0.78, 1.10)3
Due to fever/suspected malaria 0.55 0.62 1.12 (0.99, 1.27)
Due to poor appetite 0.05 0.04 0.75 (0.50, 1.13)3
Other reasons 0.16 0.16 1.00 (0.78, 1.28)
1n = 797 and 391 for the IFA + MMN and LNS groups, respectively. IFA + MMN, IFA group and MMN group combined; IFA group:
infants of women assigned to 60 mg Fe/d and 400 μg folic acid/d during pregnancy and 200 mg Ca/d as placebo during the first
6 mo postpartum, with no supplementation for the offspring; MMN group: infants of women assigned to multiple micronutrient
capsules containing 18 vitamins and minerals (including 20 mg Fe/d) during pregnancy and the first 6 mo postpartum, with no
supplementation for the offspring; LNS group: infants of women assigned to 20 g LNS/d with the same micronutrients as the
MMN group during pregnancy and the first 6 mo postpartum, and with the offspring assigned to 20 g LNS/d (for infants) containing
6 mg Fe/d from 6 to 18 mo of age. The LNS products also contained calcium, phosphorous, potassium, and magnesium as well
as macronutrients. All supplements were intended for daily consumption. Treatment points are defined to include hospitals, clinics,
health posts, private physicians, pharmacists, nurses, midwives, drug stores not operated by pharmacists, and traditional healers,
typically used by residents of the area. There is no row for diarrhea based on mothers’ definition because visits to treatment points
due to caregivers’ diagnosis of diarrhea overlapped with those due to gastroenteritis. We elected to show visits due to gastroenteritis
only, to avoid double-reporting. IFA, iron and folic acid; IRR, incidence rate ratio; LNS, lipid-based nutrient supplement; MMN, multiple
micronutrient supplement.
2Incidence (per 100 infant-days) was calculated by dividing the number of morbidity episodes by the total number of follow-up days,
and multiplying the results by 100. IRR is the ratio of the incidence in the treatment group to the incidence in the comparison group.
Incidence and IRR (95% CI) were generated using negative binomial regression models (SAS PROC GLIMMIX) and adjusting for the
number of follow-up days for each child.
3Noninferiority is concluded.
implemented in Ghana (65, 66). Furthermore, the relatively
small daily dose of iron (6.0 mg/d) provided in the 20 g SQ-
LNS/d,which was given to children in two 10-g portions per day
mixed with home-prepared complementary food, might reduce
the likelihood of adverse effects, compared with the provision
of a larger bolus of iron (67).
This study had several strengths and weaknesses. Strengths
include a fully randomized design with active control groups,
and intense weekly morbidity data collection along with
caregivers’ use of a calendar grid to record infants’ morbidity
and adherence to treatment. The study was originally designed
as a superiority trial (for the primary outcomes) that maintained
blinding to the group assignments to the maximum extent
possible, and the noninferiority margin used in the present
analysis was prespecified in our SAP. Such conditions are
associated with less bias in results (68). The consumption
of unintended supplements by some women in the IFA and
MMN groups may potentially be a weakness of the study,
but as previously reported (25), the percentage of follow-
up days during which the unintended exposure occurred was
relatively small (13%), and no women in the LNS group
consumed any other supplement apart from the intended SQ-
LNSs. We did not perform diagnostic tests for malaria at
the home visits, and therefore we do not know the extent
to which the caregivers’ reports or recalls of children’s fever
or suspected malaria reflected the incidence or prevalence of
“true malaria” in our sample. It is possible that there was
bias in caregiver reports of the morbidity symptoms, despite
using the morbidity calendar in most cases. This is particularly
important because blinding of mothers between the LNS and
non-LNS groups was not possible. In the South Africa study
(18), the authors speculated that the inability to blind mothers
to being in the 2 LNS groups as opposed to the no-supplement
group may have contributed to over-reporting of diarrheal
incidence in the LNS groups. A similar over-reporting of
morbidity in the LNS group due to absence of blinding may
have occurred in our study. We analyzed several prespecified
secondary outcomes simultaneously, and it is possible that some
of our findings may be due to chance, because of multiple testing
(69). These prespecified secondary outcomes were, however,
measured together at the same time (70) and highly correlated
(71). Under such circumstances, correcting for multiplicity was
considered unnecessary (71). The lower mean housing index for
the children who completed the study than for the dropouts
(suggesting lower background socioeconomic status of the
former) could limit the generalizability of our results, although
these groups did not differ in the other 2 socioeconomic
variables, namely assets index and Household Food Insecurity
Access Scale score.
In conclusion, our data support the hypothesis that in this
semiurban setting in Ghana, the provision of SQ-LNSs to
women from early pregnancy to 6 mo postpartum, and to their
infants from 6 to 18 mo of age, does not increase the infants’
reported overall morbidity from birth to 6 mo of age, or from
6 to 18 mo of age. Further research is needed to understand
contextual differences in the effects of nutritional supplements
on diarrhea and malaria between children in different study
settings.
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